Get the Stockscreener App
5.70
3.06%
-0.18
After Hours:
5.63
-0.07
-1.23%
Abeona Therapeutics Inc stock is traded at $5.70, with a volume of 283.99K.
It is down -3.06% in the last 24 hours and down -5.00% over the past month.
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel AIM.
See More
Previous Close:
$5.88
Open:
$5.85
24h Volume:
283.99K
Relative Volume:
1.03
Market Cap:
$249.52M
Revenue:
-
Net Income/Loss:
$-54.19M
P/E Ratio:
-2.2093
EPS:
-2.58
Net Cash Flow:
$-37.34M
1W Performance:
+2.89%
1M Performance:
-5.00%
6M Performance:
+28.96%
1Y Performance:
+16.33%
1-Day Range:
$5.67
$5.93
1-Week Range:
$5.40
$6.06
52-Week Range:
$3.05
$9.01
Abeona Therapeutics Inc Stock (ABEO) Company Profile
Name
Abeona Therapeutics Inc
Sector
Industry
Phone
646-813-4701
Address
6555 CARNEGIE AVE, 4TH FLOOR, CLEVELAND, NY
Compare ABEO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABEO
Abeona Therapeutics Inc
|
5.70 | 249.52M | 0 | -54.19M | -37.34M | -2.58 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.32 | 122.13B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
710.00 | 78.30B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
646.64 | 39.73B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
276.19 | 35.50B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.61 | 28.47B | 3.30B | -501.07M | 1.03B | -2.1146 |
Abeona Therapeutics Inc Stock (ABEO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-03-24 | Initiated | H.C. Wainwright | Buy |
| May-30-24 | Initiated | Stifel | Buy |
| Nov-11-20 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Sep-18-20 | Initiated | B. Riley FBR | Buy |
| Feb-10-20 | Initiated | SVB Leerink | Outperform |
| Dec-10-19 | Resumed | Cantor Fitzgerald | Neutral |
| Aug-15-19 | Downgrade | Maxim Group | Buy → Hold |
| Aug-12-19 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Jul-26-19 | Downgrade | Mizuho | Buy → Neutral |
| Jun-27-19 | Initiated | Mizuho | Buy |
| Oct-12-18 | Initiated | Mizuho | Buy |
| Jun-05-18 | Initiated | Seaport Global Securities | Buy |
| Nov-08-17 | Initiated | SunTrust | Buy |
| Oct-16-17 | Reiterated | H.C. Wainwright | Buy |
| Oct-11-17 | Reiterated | Cantor Fitzgerald | Overweight |
| Oct-10-17 | Initiated | Citigroup | Buy |
| Oct-05-17 | Reiterated | Maxim Group | Buy |
| Sep-15-17 | Initiated | RBC Capital Mkts | Outperform |
| Jul-18-17 | Reiterated | Maxim Group | Buy |
| Jun-22-17 | Resumed | Jefferies | Buy |
| Jan-06-17 | Initiated | Jefferies | Buy |
| Sep-29-16 | Reiterated | Maxim Group | Buy |
View All
Abeona Therapeutics Inc Stock (ABEO) Latest News
Abeona Therapeutics Inc.'s (NASDAQ:ABEO) Shift From Loss To Profit - Yahoo Finance
Dystrophic Epidermolysis Bullosa Market to Reach New Heights - openPR
Abeona Therapeutics (NASDAQ:ABEO) Raised to Hold at StockNews.com - Defense World
Abeona Therapeutics (NASDAQ:ABEO) Upgraded by StockNews.com to "Hold" Rating - MarketBeat
Abeona Therapeutics Inc (NASDAQ:ABEO) Director Sells $21,520.00 in Stock - MarketBeat
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Abeona's Strategic Move: 13,000 Restricted Shares Granted to Key New Hires - StockTitan
Insider Sell: Mark Alvino Sells 4,000 Shares of Abeona Therapeutics Inc (ABEO) - GuruFocus.com
JPMorgan Chase & Co. Buys 28,606 Shares of Abeona Therapeutics Inc (NASDAQ:ABEO) - Defense World
Abeona Therapeutics: Despite Some Competitive Pressure, This Looks Undervalued (ABEO) - Seeking Alpha
Mark Alvino Sells 4,000 Shares of Abeona Therapeutics Inc (NASDAQ:ABEO) Stock - MarketBeat
Abeona Therapeutics director Mark Alvino sells $20,400 in stock - Investing.com
(ABEO) Investment Analysis and Advice - Stock Traders Daily
Abeona Therapeutics Inc (NASDAQ:ABEO) Stake Cut by Barclays PLC - Defense World
Jane Street Group LLC Invests $84,000 in Abeona Therapeutics Inc (NASDAQ:ABEO) - Defense World
Abeona Therapeutics (NASDAQ:ABEO) Stock Rating Lowered by StockNews.com - Defense World
(ABEO) Trading Advice - Stock Traders Daily
Abeona Therapeutics (NASDAQ:ABEO) Cut to Sell at StockNews.com - MarketBeat
Abeona Therapeutics Inc (NASDAQ:ABEO) Shares Acquired by Geode Capital Management LLC - Defense World
Abeona Therapeutics Inc (NASDAQ:ABEO) Shares Sold by Barclays PLC - Defense World
State Street Corp Sells 2,600 Shares of Abeona Therapeutics Inc (NASDAQ:ABEO) - Defense World
Global Mucopolysaccharidosis Treatment Market to Witness Robust Growth, Projected to Reach USD 5,014.5 Million by 2035 Growing at a CAGR of 5.9% | FMI - GlobeNewswire Inc.
Abeona Therapeutics Awards Equity Incentives to New Employees in Strategic Talent Acquisition Move - StockTitan
Abeona Therapeutics (NASDAQ:ABEO) Upgraded to "Hold" at StockNews.com - MarketBeat
StockNews.com Upgrades Abeona Therapeutics (NASDAQ:ABEO) to “Hold” - Defense World
Owning 43% shares,institutional owners seem interested in Abeona Therapeutics Inc. (NASDAQ:ABEO), - Yahoo Finance
Abeona Therapeutics Inc. Receives Stockholder Approval for Equity Incentive Plan Amendment - Defense World
Abeona Therapeutics (NASDAQ:ABEO) Raised to “Hold” at StockNews.com - Defense World
StockNews.com Upgrades Abeona Therapeutics (NASDAQ:ABEO) to Hold - MarketBeat
(ABEO) On The My Stocks Page - Stock Traders Daily
Charles Schwab Investment Management Inc. Purchases Shares of 23,850 Abeona Therapeutics Inc (NASDAQ:ABEO) - Defense World
StockNews.com Downgrades Abeona Therapeutics (NASDAQ:ABEO) to Sell - Defense World
Abeona Therapeutics (NASDAQ:ABEO) Rating Lowered to Sell at StockNews.com - MarketBeat
When the Price of (ABEO) Talks, People Listen - Stock Traders Daily
Abeona Therapeutics Inc (NASDAQ:ABEO) is Western Standard LLC's 3rd Largest Position - MarketBeat
Abeona Therapeutics Inc (NASDAQ:ABEO) Holdings Lowered by Ikarian Capital LLC - MarketBeat
Abeona Therapeutics Inc reports results for the quarter ended September 30Earnings Summary - XM
Abeona Therapeutics announces new employee inducement grants - TipRanks
Abeona Therapeutics Grants 44,700 Restricted Shares to New Employees as Incentive - StockTitan
Walleye Capital LLC Sells 129,083 Shares of Abeona Therapeutics Inc (NASDAQ:ABEO) - MarketBeat
Abeona Therapeutics Inc.'s (NASDAQ:ABEO) large institutional owners must be happy as stock continues to impress, up 11% over the past week - Simply Wall St
What is HC Wainwright's Estimate for ABEO FY2024 Earnings? - MarketBeat
Abeona Therapeutics Inc (NASDAQ:ABEO) Shares Sold by Propel Bio Management LLC - MarketBeat
Abeona shares retain Buy rating; H.C. Wainwright sees approval potential for pz-cel in RDEB - Investing.com UK
Abeona Therapeutics (NASDAQ:ABEO) Earns "Buy" Rating from HC Wainwright - MarketBeat
Earnings call: Abeona Therapeutics Q3 2024 results and PZ cell update - Investing.com Canada
Abeona Therapeutics Inc Stock (ABEO) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.09%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):